ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care

In response to the growing problem of the abuse, misuse and diversion of Extended Release/Long Acting (ER/LA) Opioid drugs, the FDA approved a risk evaluation and mitigation strategy (REMS) for ER/LA opioid medications on July 9, 2012. The ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care course was developed by nationally renowned experts from CO*RE(Collaborative for REMS Education) and incorporates all six units defined by the FDA blueprint for REMS education. ASAM's 3-hour REMS course consists of CO*RE-branded material but also provides a 30-minute unit addressing ER/LA opioids and addiction. Participants who complete the online REMS course will earn 3 CME.

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

1. On the right hand side, locate the box labeled “Introduction" and click the blue button labeled “View Video."
2. After you have watched the video locate the next video box and click the blue button labeled “View Video."
3. After you have watched each video, select the box labeled “Test" and click the blue button labeled “Take Quiz."
4. Once you have passed the quiz, select the box labeled “Course Evaluation" and click the blue button labeled “Fill Out Survey".
5. Once you have completed the Course Evaluation, select the box labeled “Credit" and click the blue button labeled “Claim Medical Credits." You have now received credit for the session. You can view or print your certificate at any point by coming back to this session page.

CME Information and Disclosure Listing

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

The American Society of Addiction Medicine designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 3 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM CME Committee

ASAM REMS Program Planning Committee

ASAM REMS Course Faculty

ASAM CME Committee Reviewers

Learners will be able to:

• Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy, as well as possible misuse.
• Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques, as well as appropriate discontinuation strategies.
• Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
• Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
• Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.

The intended audience is all prescribers of ER/LA Opioids which includes: pain specialists, primary care physicians, physician assistants, nurse practitioners, advanced practice nurses, dentists, addiction medicine physicians, psychiatrists and other physicians and clinicians.

Acknowledgement

Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.